Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Non Operating Income (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Non Operating Income for 11 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 525.62% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.9 million through Dec 2025, down 33.93% year-over-year, with the annual reading at $12.3 million for FY2025, 1872.19% up from the prior year.
  • Non Operating Income hit $2.5 million in Q4 2025 for Voyager Therapeutics, up from $400000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $4.9 million in Q2 2024 to a low of -$8.6 million in Q4 2023.
  • Historically, Non Operating Income has averaged $1.4 million across 5 years, with a median of $1.4 million in 2022.
  • Biggest five-year swings in Non Operating Income: crashed 3236.96% in 2021 and later skyrocketed 163500.0% in 2024.
  • Year by year, Non Operating Income stood at $397000.0 in 2021, then soared by 140.05% to $953000.0 in 2022, then tumbled by 998.95% to -$8.6 million in 2023, then skyrocketed by 104.69% to $402000.0 in 2024, then soared by 525.62% to $2.5 million in 2025.
  • Business Quant data shows Non Operating Income for VYGR at $2.5 million in Q4 2025, $400000.0 in Q3 2025, and $3.3 million in Q2 2025.